Every 10-Q that Nexalin Technology, Inc. (NXL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXL filings page.
Nexalin Technology, Inc. reported very limited revenue and larger losses for the quarter ended June 30, 2026 while advancing key clinical and product initiatives. Revenue was $12,161 for the quarter and $27,111 for the first six months of 2026, down sharply from the same periods in 2025, reflecting lower international equipment sales.
The company recorded a quarterly net loss of $2,239,170 and a six‑month net loss of $4,336,007. Cash used in operating activities was $3,514,616 for the first half of 2026, leaving cash and equivalents of $1,004,958 and working capital of about $377,000 at June 30, 2026. Management concluded there is substantial doubt about Nexalin’s ability to continue as a going concern over the next 12 months without additional financing.
During the period, Nexalin initiated an FDA‑cleared clinical trial of its Gen‑3 HALO device for insomnia and continued FDA interactions on its Gen‑2 SYNC system for Alzheimer’s and dementia. It also acquired PONM, Inc., recording about $712,870 of licensed software and intellectual property to support its Nexalin NeuroCare™ digital health platform. Nasdaq notified the company that it is out of compliance with the $1.00 minimum bid price requirement; a staff delisting determination has been issued and the company has requested a hearing while considering a shareholder‑authorized reverse stock split.
Nexalin Technology, Inc. reported another quarterly loss while highlighting serious liquidity risk and Nasdaq listing pressure. For the quarter ended March 31, 2026, revenue was only $14,950, down 64% from $41,015 a year earlier, as international equipment sales softened. The company posted a net loss of $2,096,837, slightly worse than the prior-year loss of $1,988,337, and used $1,712,988 of cash in operating activities.
As of March 31, 2026, Nexalin held $1,207,895 in cash and cash equivalents and $1,500,590 in short-term investments, with working capital of $2,481,790. It raised $756,421 of net proceeds by selling 1,395,300 shares through its at-the-market equity program, bringing total ATM gross proceeds to about $1,423,000.
Management states that recurring losses, negative operating cash flow and limited resources create substantial doubt about Nexalin’s ability to continue as a going concern for at least twelve months. The company also received a Nasdaq notice on January 21, 2026 for failing to meet the $1.00 minimum bid price requirement and has until July 20, 2026 to regain compliance. Nexalin continues to advance its Gen-2 SYNC and Gen-3 HALO neurostimulation devices, including signing a roughly $944,820 scope of work with Lindus Health for a pivotal insomnia study.
Nexalin Technology (NXL) filed its Q3 2025 report, highlighting continued operating losses and a going concern warning. Revenue was $18,149 for the quarter, down from $36,031 a year ago, as legacy licensing and equipment sales remained modest. Net loss for Q3 was $2,276,311 versus $2,448,257 in Q3 2024. For the nine months, revenue totaled $129,752 and net loss reached $5,845,635.
Liquidity and capital: Cash and cash equivalents were $590,075 with short‑term investments of $3,762,602, supporting total current assets of $4,817,378 against current liabilities of $357,524. Stockholders’ equity rose to $4,768,416, aided by 2025 equity issuances, including a May/June public offering of 4,090,000 shares with gross proceeds of $5,317,000. The company amended its equity distribution agreement in October to permit ATM sales up to $10,000,000; as of October 15, $4,273,859 remained available under baby shelf limits and 157,000 shares had been sold.
Operations and R&D: Operating expenses were $2,359,832 in Q3, driven by SG&A, salaries, and stock‑based compensation. The company disclosed a substantial accumulated deficit of $90,490,866 and stated there is substantial doubt about its ability to continue as a going concern. On the regulatory front, the FDA accepted a Q‑Submission in October for the Gen‑2 SYNC system targeting Alzheimer’s and dementia, enabling a formal meeting later this year.